Бисопролол – высокоселективный β-адреноблокатор:клиническая фармакология и опыт при лечениисердечно-сосудистых заболеваний
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Список литературы
1. Cruickshank JM, Prichard BNC. Beta-blockers in clinical practice. 2nd edition. Edinburg; Churchill Livingstone, 1994.
2. Сидоренко Б.А., Преображенский Д.В. Клиническое применение бета-адреноблокаторов. М., 1994.
3. Сидоренко Б.А., Преображенский Д.В. Бета-адреноблокаторы. М., 1996.
4. The Task Force on beta-blockers of the European Society of Cardiology. Expert consensus document on β-adrenergic receptor blockers. Eur Heart J 2004; 25: 1341–62.
5. Cruickshank JM. The place of beta-blockers in cardiovascular medicine. Cardiologia 1995; 40: 829–43.
6. Weir MR, Bolli P, Prichard BNC, Weber MA. Bisoprolol. In: Messerli F.H. (ed) Cardiovascular drug therapy. 2nd ed. Philadelphia et al., 1999; p. 557–68.
7. Сидоренко Б.А., Преображенский Д.В. Диагностика и лечение артериальной гипертензии. Часть вторая. М., 2000.
8. Gress T, Nieto F, Shahar E et. al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000; 342: 905–12.
9. Westfall TC, Westfall. Adrenergic agonists and antagonists. In: Goodman & Gilman. The pharmacological basis of therapeutics. 11th ed. New York et al., 2006; p. 237–95.
10. Broekman CP, Haensel SM, van de Ven LL, Slob AK. Bisoprolol and hypertension: effects on sexual functioning in men. K.Sex Marital Ther 1992; 18: 325–31.
11. Bethge H, Leopold G, Wagner G. Bisoprolol in angina pectoris. Cardiovasc. Drug Review 1991; 9: 110–22.
12. von Arnim T, for the TIBBS Investigators. Medical treatment to reduce total ischemic burden: Total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. JACC 1995; 25: 231–8.
13. von Arnim T, for the TIBBS Investigators. Prognostic significance of transient ischemic episodes: response to treatment shows improved prognosis. JACC 1996; 28: 20–40.
14. Остроумова О.Д. Возможности применения высокоселективных β-блокаторов у больных с сопутствующими заболевания. Рус. мед. журн. 2004; 12: 721–5.
15. Buhler FR, Berglund G, Anderson OK et al. Double-blind of the cardioselective β-blockers bisoprolol and atenolol in hypertension: the Bisoprolol International Multicenter Study (BIMS). J Cardiovasc Pharmacol 1986; 8 (suppl. 11): S122–30.
16. Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after administration in hypertensive patients following 4 weeks of treatment with bisoprolol and metoprolol in hypertension: A randomized multicenter double-blind study (BISOMET). Eur Heart J 1987; 8 (97): 13S122-S130.
17. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. Circulation 1994; 90: 1765–73.
18. CIBIS-II Investigators and Committees. Cardiac Insufficiency Bisoprolol Study (CIBIS-II): a randomised trial. Lancet 1999; 353 (9146): 9–13.
19. McGavin JK, Keating GM. Bisoprolol. A review of its use in chronic heart failure. Drugs 2002; 62: 2677–96.
2. Сидоренко Б.А., Преображенский Д.В. Клиническое применение бета-адреноблокаторов. М., 1994.
3. Сидоренко Б.А., Преображенский Д.В. Бета-адреноблокаторы. М., 1996.
4. The Task Force on beta-blockers of the European Society of Cardiology. Expert consensus document on β-adrenergic receptor blockers. Eur Heart J 2004; 25: 1341–62.
5. Cruickshank JM. The place of beta-blockers in cardiovascular medicine. Cardiologia 1995; 40: 829–43.
6. Weir MR, Bolli P, Prichard BNC, Weber MA. Bisoprolol. In: Messerli F.H. (ed) Cardiovascular drug therapy. 2nd ed. Philadelphia et al., 1999; p. 557–68.
7. Сидоренко Б.А., Преображенский Д.В. Диагностика и лечение артериальной гипертензии. Часть вторая. М., 2000.
8. Gress T, Nieto F, Shahar E et. al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000; 342: 905–12.
9. Westfall TC, Westfall. Adrenergic agonists and antagonists. In: Goodman & Gilman. The pharmacological basis of therapeutics. 11th ed. New York et al., 2006; p. 237–95.
10. Broekman CP, Haensel SM, van de Ven LL, Slob AK. Bisoprolol and hypertension: effects on sexual functioning in men. K.Sex Marital Ther 1992; 18: 325–31.
11. Bethge H, Leopold G, Wagner G. Bisoprolol in angina pectoris. Cardiovasc. Drug Review 1991; 9: 110–22.
12. von Arnim T, for the TIBBS Investigators. Medical treatment to reduce total ischemic burden: Total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. JACC 1995; 25: 231–8.
13. von Arnim T, for the TIBBS Investigators. Prognostic significance of transient ischemic episodes: response to treatment shows improved prognosis. JACC 1996; 28: 20–40.
14. Остроумова О.Д. Возможности применения высокоселективных β-блокаторов у больных с сопутствующими заболевания. Рус. мед. журн. 2004; 12: 721–5.
15. Buhler FR, Berglund G, Anderson OK et al. Double-blind of the cardioselective β-blockers bisoprolol and atenolol in hypertension: the Bisoprolol International Multicenter Study (BIMS). J Cardiovasc Pharmacol 1986; 8 (suppl. 11): S122–30.
16. Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after administration in hypertensive patients following 4 weeks of treatment with bisoprolol and metoprolol in hypertension: A randomized multicenter double-blind study (BISOMET). Eur Heart J 1987; 8 (97): 13S122-S130.
17. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. Circulation 1994; 90: 1765–73.
18. CIBIS-II Investigators and Committees. Cardiac Insufficiency Bisoprolol Study (CIBIS-II): a randomised trial. Lancet 1999; 353 (9146): 9–13.
19. McGavin JK, Keating GM. Bisoprolol. A review of its use in chronic heart failure. Drugs 2002; 62: 2677–96.
Авторы
Д.В.Преображенский, И.Д.Вышинская,Н.И.Некрасова
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.